Organon & Co.: Migraine Disorders trials

The registry lists 16 Migraine Disorders studies with Organon & Co. as lead sponsor. 0 are open to participants now and 12 have results posted.

Phase 1 1Phase 3 15(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029)CompletedNCT01286207Phase 3Results posted
• A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)CompletedNCT01004263Phase 3Results posted
• A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)CompletedNCT01001234Phase 3Results posted
• Treatment of Multiple Attacks of Acute Migraine (0462-025)CompletedNCT00899379Phase 3Results posted
• Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)CompletedNCT00898677Phase 3Results posted
• MK0462 in Treatment of Migraine With Recurrence (MK0462-022)CompletedNCT00897949Phase 3Results posted
• MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)CompletedNCT00897104Phase 3Results posted
• A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)CompletedNCT00894556Phase 3Results posted
• A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine ProphylaxisCompletedNCT00812006Phase 3Results posted
• Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1)CompletedNCT00604812Phase 1Results posted
• Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)CompletedNCT00516737Phase 3Results posted
• Study to Test a Marketed Product in the Treatment of Migraine-associated NauseaCompletedNCT00250458Phase 3Results posted
• Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072)CompletedNCT00111722Phase 3
• Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071)CompletedNCT00111709Phase 3
• Study to Test an Approved Product in the Early Treatment of Migraine (0462-066)CompletedNCT00095004Phase 3
• Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)CompletedNCT00092963Phase 3